|Day Low/High||87.33 / 89.09|
|52 Wk Low/High||62.66 / 92.99|
We're seeing lots of companies snapping up their peers, and the market is applauding.
Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.
There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
Let's take a fresh look.
These stocks are priced for total imperfection. That's just what you want.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Right now, AbbVie is the best way to capitalize on the moment and on the future.
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Plus, Intel results crush expectations and Starbucks solidifies its comeback.
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...
It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
With no other bidder expected to emerge, this is a high risk arbitrage play.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's look closer at the charts and indicators of ABBV.
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.